Neural Therapeutics Inc. NURL
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 122.61% | 136.43% | 127.93% | 22.15% | -36.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.16% | 51.01% | 41.66% | -12.65% | -44.22% |
| Operating Income | -62.16% | -51.01% | -41.66% | 12.65% | 44.22% |
| Income Before Tax | -124.38% | -54.95% | -47.06% | -110.32% | 33.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.38% | -54.95% | -47.06% | -110.32% | 33.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.38% | -54.95% | -47.06% | -110.32% | 33.72% |
| EBIT | -62.16% | -51.01% | -41.66% | 12.65% | 44.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -56.67% | -22.22% | -15.66% | -41.49% | 55.56% |
| Normalized Basic EPS | -50.00% | -20.00% | -15.69% | 39.19% | 61.62% |
| EPS Diluted | -56.67% | -22.22% | -15.66% | -41.49% | 55.56% |
| Normalized Diluted EPS | -50.00% | -20.00% | -15.69% | 39.19% | 61.62% |
| Average Basic Shares Outstanding | 82.90% | 55.84% | 25.25% | 29.34% | 40.31% |
| Average Diluted Shares Outstanding | 82.90% | 55.84% | 25.25% | 29.34% | 40.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |